John Parkinson

Berkeley Heights, NJ-based biopharmaceutical company, CorMedix, is working towards an expanded indication for its DefenCath product, for the prevention of these healthcare-associated infections.

With the recent phase 3 data results of the Moderna COVID-19-influenza combination vaccine, the company is working towards regulatory approval and opens the door to possible protection against multiple viruses with less immunizations.

The state's attorney general filed the lawsuit against Pfizer for its ‘misleading statements’ about the vaccine.

New research offers clues to susceptibility for the antiviral as the CDC updates the public on 2 strains circulating globally.

A study points to inpatients who were 50 years and older with the respiratory illness suffering from heart-related complications with the largest number of them having acute heart failure. 

Seres is selling their microbiota product to Nestlé and expects to make a smooth transition as they already have an existing partnership.

The company announced data this morning for its investigational mRNA-1083 vaccine and plans to continue collecting data and working towards submitting a Biological License Application (BLA) for it.

The federal agency’s decision expands the vaccine’s eligibility to people 50 years of age and older, making it the first one for this age group.

FDA VRBPAC recommends protection against JN1 for the fall COVID-19 vaccines, a multidrug-resistant form of gonorrhea gives cause for concern, piperacillin-tazobactam shown to have higher mortality than cefepime for sepsis, and more this week from Contagion.

Although there is a rise in the FLiRT family of mutations, the committee decided to seek protection against the older strain.

Atea pharmaceuticals is presenting data at a European liver conference this week showing a high efficacy for its combination therapy at 12 weeks post-treatment.

A continued clarion call is being sounded about the drug-resistant pathogen.

The organization included numerous bacterium that are seen as critical threats to patients.

The clearance rate varied across states, but were not close to the 2025 or 2030 goals across all jurisdictions.

The company’s mRNA 1345 vaccine was given the nod by the federal agency and is indicated for seniors for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD).

This is the second case in Michigan and it is confirmed in another farmworker who worked with infected cattle.

Twenty people were reportedly sickened by a naturally occurring biotoxin after gathering mussels from beaches in Oregon.

Minnie Hatch was in her late teens when she was diagnosed with the infection. Since then, she has had recurrent episodes and dealt with care challenges along the way.

Deaths varied greatly depending on the age group, with the oldest population having the highest rates.

A new series reviewing antimicrobial resistance (AMR) reduction strategies shows that available vaccines, water and sanitation, and infection control methods could greatly reduce the mortality associated with this major health crisis.

The flight originated from Germany then landed in Los Angeles and made a final stop in Fresno, California with the infected individual. CDC is aiding in tracking down people on these flights to find out exposure risks.

This framework in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from animals to humans.

As the summer celebrations begin, food safety remains vital to everyone.

In a human challenge, an investigational spray, Neumifil (HEX17), manufactured by Pneumagen, reported its results at the recent American Thoracic Society meeting.

Study results on Vowst were presented at the recent DDW conference.

A Michigan farmworker who had regular contact with livestock was confirmed to have contracted the virus.

A newer strategic approach combined with existing treatments are together trying to reduce incidence rates and cure people of HCV, but barriers to treatment remain, and often leave people outside the continuum of care.

Public health officials have confirmed 5 cases since mid-March with a separate case associated with a grocery store employee.

The novel vaccine, ARCT-154, is a self-amplifying messenger RNA (sa-mRNA) vaccine and now has the first published demonstration of clinical efficacy for this type of vaccine.

Both the World Health Organization and FDA have now recommended this particular set of viruses be left off influenza vaccines for the 2024-2025 respiratory virus season. A new study points to further evidence of their extinction.